COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article Access statistics

Viewed: 794

Emailed: 0

PDF Downloaded: 218

IP Indian Journal of Immunology and Respiratory Medicine

Delamanid- A ray of hope for drug resistant tuberculosis

Full Text PDF Share on Facebook Share on Twitter

Author Details : Mohammad Atif, Mohd Maroof, Sankalp Yadav

Volume : 2, Issue : 3, Year : 2017

Article Page : 66-68

Suggest article by email


The emergence of drug-resistant tuberculosis is a major threat to tuberculosis care and control throughout the world. The lack of effective, affordable and safe drugs for the treatment of MDR-TB is a key factor in the inability of programs to boost up their treatment efforts to meet national and global targets. Delamanid, a newer mycobacterial cell wall synthesis inhibiting drug, received a conditional approval from European medicines agency for the treatment of MDR-TB. Delamanid, in addition to its previously demonstrated efficacy in pulmonary tuberculosis, might be an effective therapeutic approach to treating extra pulmonary tuberculosis. Treatment with Delamanid for 6 months in combination with an optimized regimen can improve patient outcomes and reduce mortality and morbidity among patients with both multidrug-resistant (MDR) and extensively drug-resistant TB (XDR).

: Delamanid; Efficacy; MDR-TB; Tuberculosis

How to cite : Atif M, Maroof M, Yadav S, Delamanid- A ray of hope for drug resistant tuberculosis. IP Indian J Immunol Respir Med 2017;2(3):66-68

Copyright © 2017 by author(s) and IP Indian J Immunol Respir Med. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (